These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6196551)

  • 1. Pharmacokinetics and pharmacodynamics of the 5-HT2 receptor antagonist ketanserin in man.
    Trenk D; Mosler A; Kirch W; Meinertz T; Jähnchen E
    J Cardiovasc Pharmacol; 1983; 5(6):1034-9. PubMed ID: 6196551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ketanserin in man.
    Reimann IW; Okonkwo PO; Klotz U
    Eur J Clin Pharmacol; 1983; 25(1):73-6. PubMed ID: 6617728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of propranolol on the steady-state plasma levels of ketanserin.
    Trenk D; Lühr A; Radkow N; Jähnchen E
    Arzneimittelforschung; 1985; 35(8):1286-8. PubMed ID: 2934070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients.
    Hedner T; Pettersson A; Persson B
    J Hypertens Suppl; 1986 Apr; 4(1):S91-3. PubMed ID: 2939221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of antihypertensive action of ketanserin in man.
    Reimann IW; Frölich JC
    Br Med J (Clin Res Ed); 1983 Aug; 287(6389):381-3. PubMed ID: 6135489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ketanserin, an antihypertensive agent with specific 5-HT2-receptor blocking activity, on intracranial pressure.
    Van Aken H; Anger C; Puchstein C; Thijs J; Lawin P
    Crit Care Med; 1984 Jan; 12(1):4-7. PubMed ID: 6140126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers.
    Williams FM; Leeser JE; Rawlins MD
    Br J Clin Pharmacol; 1986 Sep; 22(3):301-8. PubMed ID: 3768242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of ketanserin in patients with essential hypertension.
    Persson B; Pettersson A; Hedner T
    Eur J Clin Pharmacol; 1987; 32(3):259-65. PubMed ID: 3595699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects.
    Gasic S; Eichler HG; Korn A
    J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and pharmacokinetics of ketanserin in elderly subjects.
    Kurowski M
    Eur J Clin Pharmacol; 1985; 28(4):411-7. PubMed ID: 3161741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension.
    Hedner T; Persson B; Berglund G
    Br J Clin Pharmacol; 1983 Aug; 16(2):121-5. PubMed ID: 6615685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketanserin and alpha 1-adrenergic antagonism in humans.
    Zabludowski JR; Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
    van de Water A; Wouters L; Xhonneux R; Reneman S
    Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent.
    Persson B; Hedner T; Henning M
    J Pharm Pharmacol; 1982 Jul; 34(7):442-5. PubMed ID: 6126541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
    Hedner T; Persson B
    Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ketanserin on the kinetics of digoxin and digitoxin.
    Ochs HR; Verburg-Ochs B; Höller M; Greenblatt DJ
    J Cardiovasc Pharmacol; 1985; 7(1):205-7. PubMed ID: 2580144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a 5-HT antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympathoadrenal function in normal man.
    Zoccali C; Zabludowski JR; Isles CG; Murray GD; Inglis GC; Robertson JI; Fraser R; Ball SG
    Br J Clin Pharmacol; 1983 Sep; 16(3):305-11. PubMed ID: 6626423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue distribution of ketanserin in rat, rabbit and dog.
    Michiels M; Monbaliu J; Meuldermans W; Hendriks R; Geerts R; Woestenborghs R; Heykants J
    Arzneimittelforschung; 1988 Jun; 38(6):775-84. PubMed ID: 3178917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity.
    Ramage AG
    Eur J Pharmacol; 1985 Jul; 113(3):295-303. PubMed ID: 2931285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.